Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4545380 | 1.00 | OPRM1 (0.98) | OPRM1OPRK1SIGMAR1 | |
| SCHEMBL8761982 | 1.00 | OPRM1 (0.98) | OPRM1OPRK1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL29878305 | 0.99 | OPRM1 (1.00) | OPRM1OPRK1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL3078699 | 0.99 | OPRM1 (1.00) | OPRM1OPRK1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL3078695 | 0.99 | OPRM1 (1.00) | OPRM1OPRK1SIGMAR1 | |
| SCHEMBL10366431 | 0.99 | OPRM1 (0.98) | OPRM1OPRK1SIGMAR1 | |
| SCHEMBL10366430 | 0.99 | OPRM1 (0.98) | OPRM1OPRK1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL10366870 | 0.98 | OPRM1 (1.00) | OPRM1OPRK1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL10366871 | 0.98 | OPRM1 (1.00) | OPRM1OPRK1SIGMAR1 | |
| SCHEMBL13828279 | 0.89 | OPRM1 (0.78) | OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0632806-B1 | AMINOCYCLOHEXYLAMIDES FOR ANTIARRHYTHMIC AND ANAESTHETIC USES | UNIV BRITISH COLUMBIA (CA) | 1997-07-02 | — | — | EP | claimed |
| EP-0632806-A1 | AMINOCYCLOHEXYLAMIDES FOR ANTIARRHYTHMIC AND ANAESTHETIC USES. | UNIV BRITISH COLUMBIA (CA) | 1995-01-11 | — | — | EP | claimed |
| WO-1993019056-A1 | AMINOCYCLOHEXYLAMIDES FOR ANTIARRHYTHMIC AND ANAESTHETIC USES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1993-09-30 | — | — | WO | claimed |
| EP-0147085-B1 | SUBSTITUTED TRANS-1.2-DIAMINOCYCLOHEXYL AMIDE COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1990-03-14 | — | — | EP | claimed |
| EP-0147085-A2 | Substituted trans-1.2-diaminocyclohexyl amide compounds | WARNER-LAMBERT COMPANY (US) | 1985-07-03 | — | — | EP | claimed |
| US-8338442-B2 | Opioid receptors antagonist ; restless leg syndrome; sleep disorders | TORAY INDUSTRIES, INC. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-7041704-B2 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050203190-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| US-20050107353-A1 | Methods of treating lower urinary tract disorders using losigamone | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | US | disclosed |
| US-20040213842-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040209960-A1 | Methods of treating lower urinary tract disorders using sodium channell modulators | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040116456-A1 | Remedies for psychoneurosis | TORAY INDUSTRIES, INC. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-0632806-B1 | AMINOCYCLOHEXYLAMIDES FOR ANTIARRHYTHMIC AND ANAESTHETIC USES | UNIV BRITISH COLUMBIA (CA) | 1997-07-02 | — | — | EP | disclosed |
| US-5506257-A | SODIUM CHANNEL BLOCKERS | UNIVERSITY OF BRITISH COLUMBIA (CA) | 1996-04-09 | — | — | US | disclosed |
| EP-0632806-A1 | AMINOCYCLOHEXYLAMIDES FOR ANTIARRHYTHMIC AND ANAESTHETIC USES. | UNIV BRITISH COLUMBIA (CA) | 1995-01-11 | — | — | EP | disclosed |
| WO-1993019056-A1 | AMINOCYCLOHEXYLAMIDES FOR ANTIARRHYTHMIC AND ANAESTHETIC USES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1993-09-30 | — | — | WO | disclosed |
| EP-0147085-B1 | SUBSTITUTED TRANS-1.2-DIAMINOCYCLOHEXYL AMIDE COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1990-03-14 | — | — | EP | disclosed |
| US-4738981-A | ANALGESICS | WARNER-LAMBERT (US) | 1988-04-19 | — | — | US | disclosed |
| US-4656182-A | ANALGESICS, DIURETICS, PSYCHOTHERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1987-04-07 | — | — | US | disclosed |
| EP-0147085-A2 | Substituted trans-1.2-diaminocyclohexyl amide compounds | WARNER-LAMBERT COMPANY (US) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203190-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | SLC10A2, TRPV1, VIPR2 | OPRM1 639/4885OPRK1 383/4885SIGMAR1 746/4885 |
| US-20040213842-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | SLC10A2, VIPR2, TRPV1 | OPRM1 637/4885OPRK1 380/4885SIGMAR1 730/4885 |
| US-20050107353-A1 | Methods of treating lower urinary tract disorders using losigamone | LPXN, TRPM5, SLC10A2 | OPRM1 77/4885OPRK1 199/4885SIGMAR1 1143/4885 |
| US-20040209960-A1 | Methods of treating lower urinary tract disorders using sodium channell modulators | CACNA1G, CACNA1D, CACNA1B | OPRM1 209/4885OPRK1 188/4885SIGMAR1 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.